Psoriatic Arthritis

Several modalities found to be effective in the triage of psoriasis patients with musculoskeletal symptoms, according to a study presented at the 2017 American College of Rheumatology meeting.

Risankizumab treats moderate to severe chronic plaque psoriasis.

Calcipotriene and betamethasone dipropionate treats mild to moderate plaque psoriasis in adult patients.

Two supplemental biologics license applications granted to golimumab to treat adults with psoriatic arthritis and adults with active ankylosing spondylitis.

Ustekinumab (Stelara) treats moderate to severe plaque psoriasis in adolescents who are candidates for phototherapy or systemic therapy.

A fire ant toxin may lead to new medications for psoriasis.

For patients with psoriasis and/or psoriatic arthritis, actual-to-expected dosing ratios and costs were lower for etanercept than for ustekinumab.

Findings may lead to future treatments for patients with psoriasis and psoriatic arthritis.

Top news of the week from Specialty Pharmacy Times.

Research finds that a robust pipeline of PsA agents will put pressure on Cosentyx.

If approved, Xeljanz will be the first Janus kinase inhibitor for psoriatic arthritis.

Renflexis is indicated for the same inflammatory conditions as reference drug infliximab.

Renflexis is a biosimilar of Remicade, which treats inflammatory conditions, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Abatacept (Orencia) receives approval for third autoimmune condition.

Orencia has already been approved for two other autoimmune conditions.

New biologic drugs coming to market could transform the standard of care.

Tofacitinib and Guselkumab show promise in patients with PsA.

Eli Lilly will present 27 abstracts on the safety and long-term efficacy for rheumatoid arthritis and psoriasis drugs.

Another state passes legislation to increase uptake of biosimilars.

The IL-17 inhibitor reduced the number of tender and swollen joints in at least 20% of patients with PsA.

Otezla has been found to improve the signs and symptoms of psoriatic arthritis.

Clobetasol propionate lotion can be used for the treatment of moderate-to-severe plaque psoriasis.

Sixty percent of patients taking guselkumab saw improvements in PsA disease symptoms.

New drugs for psoriatic arthritis discussed during a session at the ACR/ARHP conference.

Elevated rates of fibromyalgia found in patients with rheumatic diseases, such as psoriatic arthritis.

Few prior studies have evaluated the relative effectiveness of earlier and later lines of TNF therapy in psoriatic arthritis.

Few prior studies have evaluated the relative effectiveness of earlier and later lines of TNFi therapy in psoriatic arthritis.

Inflectra is the first biosimilar monoclonal antibody approved by the FDA.

Results from clinical trials of Taltz presented at the European Academy of Dermatology and Venereology Congress.

AbbVie’s experimental compound treats moderate-to-severe chronic plaque psoriasis.